Last reviewed 2026-05-26 · How we verify

Forteo Inj.

QuadMedicine · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

Forteo Inj. is a Small molecule drug developed by QuadMedicine. It is currently in Phase 1 development. Also known as: Control Drug 2.

Forteo Inj. is a parathyroid hormone receptor agonist used to treat osteoporosis. It works by activating the parathyroid hormone/parathyroid hormone-related peptide receptor, a protein-based mechanism.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Forteo Inj.
Also known as	Control Drug 2
Sponsor	QuadMedicine
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of TeriQ Patch in Healthy Adult Female Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Forteo Inj. CI brief — competitive landscape report
Forteo Inj. updates RSS · CI watch RSS
QuadMedicine portfolio CI

Frequently asked questions about Forteo Inj.

What is Forteo Inj.?

Forteo Inj. is a Small molecule drug developed by QuadMedicine.

Who makes Forteo Inj.?

Forteo Inj. is developed by QuadMedicine (see full QuadMedicine pipeline at /company/quadmedicine).

Is Forteo Inj. also known as anything else?

Forteo Inj. is also known as Control Drug 2.

What development phase is Forteo Inj. in?

Forteo Inj. is in Phase 1.

Manufacturer: QuadMedicine — full pipeline
Also known as: Control Drug 2

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing